Lumify Preservative Free Patent Expiration

Lumify Preservative Free is a drug owned by Bausch And Lomb Inc. It is protected by 3 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 14, 2030. Details of Lumify Preservative Free's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11596600 Vasoconstriction compositions and methods of use
Jul, 2029

(4 years from now)

Active
US9259425 Compositions and methods for eye whitening
Jul, 2030

(5 years from now)

Active
US8293742 Preferential vasoconstriction compositions and methods of use
Jul, 2030

(5 years from now)

Active


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Lumify Preservative Free and ongoing litigations to help you estimate the early arrival of Lumify Preservative Free generic.

Lumify Preservative Free's Litigations

Lumify Preservative Free has been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 04, 2021, against patent number US9259425. The petitioner Slayback Pharma LLC, challenged the validity of this patent, with Eye Therapies, LLC as the respondent. Click below to track the latest information on how companies are challenging Lumify Preservative Free's patents.

Last updated on September 3, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US11596600 February, 2024 Pending Eye Therapies, LLC et al. Dr. Reddy's Laboratories S.A. et al.
US8293742 November, 2021 Final Written Decision - Appealed
(15 May, 2023)
Eye Therapies, LLC et al. Slayback Pharma LLC et al.
US9259425 November, 2021 Terminated-Settled
(05 Oct, 2022)
Eye Therapies, LLC Slayback Pharma LLC

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Lumify Preservative Free is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lumify Preservative Free's family patents as well as insights into ongoing legal events on those patents.

Lumify Preservative Free's Family Patents

Lumify Preservative Free has patent protection in a total of 16 countries. It has a significant patent presence in the US with 62.7% of its patents being US patents. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Lumify Preservative Free.

Family Patents



Generic Launch

Generic Release Date:

Lumify Preservative Free's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 14, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Lumify Preservative Free Generics:

Brimonidine Tartrate is the generic name for the brand Lumify Preservative Free. 12 different companies have already filed for the generic of Lumify Preservative Free, with Sandoz having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lumify Preservative Free's generic

Lumify Preservative Free Competitors

Understanding your competition is essential for market success. There are several other brand drugs in the same treatment category and using the same active ingredient (Brimonidine Tartrate) as Lumify Preservative Free. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bausch And Lomb Inc
Lumify

(uses Brimonidine Tartrate)

Used for relieving redness in the eyes caused by minor eye irritations.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Brimonidine Tartrate. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Abbvie
Alphagan P
Combigan
Alcon Labs Inc
Simbrinza
Galderma Labs Lp
Mirvaso
Sandoz
Qoliana


Apart from brand drugs containing the same ingredient, some generics have also been filed for Brimonidine Tartrate, Lumify Preservative Free's active ingredient. Check the complete list of approved generic manufacturers for Lumify Preservative Free





About Lumify Preservative Free

Lumify Preservative Free is a drug owned by Bausch And Lomb Inc. Lumify Preservative Free uses Brimonidine Tartrate as an active ingredient. Lumify Preservative Free was launched by Bausch And Lomb Inc in 2024.

Approval Date:

Lumify Preservative Free was approved by FDA for market use on 19 April, 2024.

Active Ingredient:

Lumify Preservative Free uses Brimonidine Tartrate as the active ingredient. Check out other Drugs and Companies using Brimonidine Tartrate ingredient

Dosage:

Lumify Preservative Free is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.025% SOLUTION/DROPS Over the counter OPHTHALMIC